Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) shares traded up 3.9% on Tuesday . The stock traded as high as $0.9199 and last traded at $0.8135. Approximately 616,500 shares were traded during trading, a decline of 59% from the average session volume of 1,521,488 shares. The stock had previously closed at $0.7828.
Qualigen Therapeutics Trading Up 3.9%
The company has a market capitalization of $1.38 million, a PE ratio of -0.11 and a beta of 0.24. The business’s fifty day moving average is $0.93 and its two-hundred day moving average is $1.16.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
Further Reading
- Five stocks we like better than Qualigen Therapeutics
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
